DBL ASCORBIC ACID 500mg/5mL USP Injection

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

ascorbic acid, Quantity: 100 mg/mL

Disponibbli minn:

Phebra Pty Ltd

Għamla farmaċewtika:

Injection, solution

Kompożizzjoni:

Excipient Ingredients: sodium bicarbonate; sodium chloride; thiourea; benzyl alcohol; water for injections

Rotta amministrattiva:

Intramuscular, Intravenous, Subcutaneous

Unitajiet fil-pakkett:

50x500mg/5mL

Tip ta 'preskrizzjoni:

Not scheduled. Not considered by committee

Indikazzjonijiet terapewtiċi:

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code) Prevention and treatment of ascorbic acid deficiency (i.e. scurvy) when oral therapy is contraindicated. As a supplement during periods of increases requirements, only if needs cannot be met from normal dietary sources and oral supplemental therapy is contraindicated, e.g. wound healing, burns, infections, trauma, post-operatively and in thyrotoxicosis. As an adjunct in the treatment of idiopathic methaemoglobinaemia. The use ascorbic acid with desferrioxamine therapy to increase iron excretion remains unsubstantiated. Injectable ascorbic acid is administrated for the above indications where oral administration is not possible, or in which medication given by the oral route will not be sufficiently absorbed. INDICATIONS AS AT 8 January 2004: Prevention and treatment of ascorbic acid deficiency (i.e. scurvy) when oral therapy is contraindicated. As a

Sommarju tal-prodott:

Visual Identification: Clear colourless solution; Container Type: Ampoule; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

1991-10-08